The report "Global Aptamers Market, By Type (Nucleic Acid and Peptides (DNA-Based Aptamers, RNA-Based Aptamers, and XNA-Based Aptamers)), By Application (Diagnostics, Therapeutics, and Research and Development), and Region - Global Forecast to 2030"
aptamers market is projected to grow from US$ 205.40 million in 2019 to US$ 985.44 million by 2030. Advancements in aptamer development technologies, increasing R&D expenditure, and the rising number of companies investing in this market are the major key driving factors responsible for the growth of global aptamers market. Low cost and high efficacy in binding to large molecules compared to antibodies and the patent expiration of systemic evolution of ligands by exponential enrichment technology (SELEX) which boosts the global market positively.
Key Highlights:
· In September 2018, Base Pair Biotechnologies was awarded for discovering aptamers to canine oncology biomarkers.
· In April 2019, Agilent and Somalogic sign agreement for supply of customized microarrays
Key Market Insights from the report:
The global aptamers market accounted for US$ 205.40 million in 2020 and is projected to register a moderate CAGR of 16.90%. over the forecast period. The market report has been segmented on the type, application, and region.
· By type, the global aptamers market is segmented into nucleic acid and peptides. The peptides is further segmented into DNA-based aptamer, RNA-based aptamers, and XNA-based aptamers.
· By application, the global aptamers market is categorized into diagnostics, therapeutics and research and development.
· By region, North America is projected to lead the global aptamers market and is expected to remain dominant, due to rapid technological advancements and high investment and funding to support the development of aptamers.
Before purchasing this report, request a sample or make an inquiry by clicking the following link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3879
The prominent player operating in the global aptamers market includes Somalogic, Inc., Noxxan Pharma AG, Aptamer Science Inc., Aptagen, Inc, AM Biotechnologies LLC, Aptamer Solutions Ltd., Aptus Biotech S.L., Base Pair Biotechnologies Inc., NeoVentures Biotechnology Inc., TriLink BioTechnologies, Inc.
